It isnβt Manufacturing Anymore.
Manufacturing processes have advanced dramatically over the past decade.
Yet many development timelines are still delayed by something much less visible.
𧬠The starting material
π€ Finding the right donor
π
Scheduling collections
β
Meeting inclusion criteria
π Coordinating logistics
βοΈ Navigating international shipping
π Managing documentation across multiple countries
These operational challenges can add weeks or even months before manufacturing begins.
As cell therapies become more personalized and globally distributed, the reliability of the supply chain becomes just as important as the manufacturing process itself.
The future of cell therapy depends not only on better engineering, but also on building stronger biological supply chains π π¬ The Biggest Bottleneck in Cell Therapy Isnβt Manufacturing Anymore
Manufacturing processes have advanced dramatically over the past decade.
Yet many development timelines are still delayed by something much less visible.
𧬠The starting material
π€ Finding the right donor
π
Scheduling collections
β
Meeting inclusion criteria
π Coordinating logistics
βοΈ Navigating international shipping
π Managing documentation across multiple countries
These operational challenges can add weeks or even months before manufacturing begins.
As cell therapies become more personalized and globally distributed, the reliability of the supply chain becomes just as important as the manufacturing process itself.
The future of cell therapy depends not only on better engineering, but also on building stronger biological supply chains π